ERDRP-0519
 | |
| Legal status | |
|---|---|
| Legal status |
|
| Identifiers | |
| |
| CAS Number |
1374006-96-8  |
| PubChem (CID) | 57521469 |
| Chemical and physical data | |
| Formula | C23H30F3N5O4S |
| Molar mass | 529.574 |
| 3D model (Jmol) | Interactive image |
| |
ERDRP-0519 is an antiviral drug which is the first drug specifically developed to target the measles morbillivirus. It acts as an inhibitor of the viral enzyme RNA polymerase which is essential for viral replication, and in animal studies showed good oral bioavailability and protected ferrets from otherwise lethal doses of a morbillivirus when administered up to three days after infection.[1][2]
See also
References
- ↑ White LK, Yoon JJ, Lee JK, Sun A, Du Y, Fu H, Snyder JP, Plemper RK (2007). "Nonnucleoside Inhibitor of Measles Virus RNA-Dependent RNA Polymerase Complex Activity". Antimicrobial Agents and Chemotherapy. 51 (7): 2293–303. doi:10.1128/AAC.00289-07. PMC 1913224
. PMID 17470652. - ↑ Krumm, S. A.; Yan, D.; Hovingh, E. S.; Evers, T. J.; Enkirch, T.; Reddy, G. P.; Sun, A.; Saindane, M. T.; Arrendale, R. F.; Painter, G.; Liotta, D. C.; Natchus, M. G.; von Messling, V.; Plemper, R. K. (2014). "An Orally Available, Small-Molecule Polymerase Inhibitor Shows Efficacy Against a Lethal Morbillivirus Infection in a Large Animal Model". Science Translational Medicine. 6 (232): 232ra52. doi:10.1126/scitranslmed.3008517. PMID 24739760.
This article is issued from Wikipedia - version of the 5/29/2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.